ABT — ABBOTT LABORATORIES

NYSE · Health Care · Pharmaceuticals · CIK 1800 ·
Last close
$90.53
Market Cap
$157.69B
52W High
$105.32
52W Low
$81.97
ADV30
13,293,305
Next earnings
2026-07-16
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 11,164,000,000 6,274,000,000 1,345,000,000 1,077,000,000 110,429,000,000 6,803,000,000 57,728,000,000
Dec 2025 11,459,000,000 6,537,000,000 2,251,000,000 1,776,000,000 86,713,000,000 8,522,000,000 33,942,000,000
Sep 2025 11,369,000,000 6,294,000,000 2,057,000,000 1,644,000,000 84,181,000,000 7,511,000,000 32,917,000,000
Jun 2025 11,142,000,000 6,288,000,000 2,052,000,000 1,779,000,000 83,999,000,000 6,951,000,000 33,170,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$9,464,000,000
Investing CF
$-22,276,000,000
Financing CF
$13,059,000,000
CapEx
$-2,086,000,000
Dividends Paid
$-4,188,000,000
Buybacks
$-793,000,000
EPS Diluted TTM
$3.57
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$49,956,000,000
Inventory
$6,989,000,000
Receivables
$11,224,000,000
ST Investments
$492,000,000
EBIT TTM
$8,673,000,000
Pretax Income TTM
$8,137,000,000
Interest Exp TTM
$536,000,000
Analysts
25

Yahoo Snapshot (yfinance, live)

Total Revenue
$45,134,000,128
EBITDA
$11,744,000,000
Free Cash Flow
$6,341,125,120
Enterprise Value
$185,167,282,176
Total Cash
$7,295,000,064
Total Debt
$34,136,000,512
Shares Out
1,741,813,154
Trailing EPS
$3.57
Book Value
$29.89
ROE
12.3%
ROA
5.6%
Div Yield
2.78%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 44,328,000,000 8,053,000,000 6,524,000,000 86,713,000,000 33,942,000,000 9,566,000,000
Dec 2024 41,950,000,000 6,825,000,000 13,402,000,000 81,414,000,000 33,513,000,000 8,558,000,000
Dec 2023 40,109,000,000 6,478,000,000 5,723,000,000 73,214,000,000 34,387,000,000 7,261,000,000
Dec 2022 43,653,000,000 8,362,000,000 6,933,000,000 74,438,000,000 37,533,000,000 9,581,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$6.06

Max Pain — expiry 2026-06-26

max pain strike: $90.00 · spot: $90.49 · call oi: 7,099 · put oi: 5,369
Expected Move to 2026-06-26: ±$1.90 (2.10%) — implied range $88.59$92.39 · ATM straddle on $90.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVO NOVO NORDISK A S $158.95B $47.42
NONOF NOVO NORDISK A S $154.49B $46.09
PFE PFIZER INC $140.89B $24.72
VRTX VERTEX PHARMACEUTICALS INC / MA $118.89B $468.42
BMY BRISTOL MYERS SQUIBB CO $113.40B $55.53

News headlines (Yahoo Finance, 1h cache)

Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy
2026-06-24 17:36 · Yahoo
MiniMed Launches Abbott's Instinct Sensors Across European Markets
2026-06-24 16:17 · Yahoo
How Are Emerging Markets Supporting Abbott's EPD Momentum?
2026-06-24 12:52 · Yahoo
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
2026-06-24 12:30 · Yahoo
MiniMed launches Abbott-made Instinct glucose sensor in Europe
2026-06-24 10:00 · Yahoo
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”
2026-06-23 14:41 · Yahoo
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
2026-06-23 13:00 · Yahoo
Abbott (ABT) Launches Similac Campaign To Ease Social Media Pressure On Young Parents
2026-06-23 09:07 · Yahoo
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
2026-06-22 22:14 · Yahoo
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
2026-06-22 16:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.